<DOC>
	<DOCNO>NCT02878681</DOCNO>
	<brief_summary>The purpose study compare effect intravitreal injection ranibizumab aflibercept systemic VEGF level DME patient detailed time course .</brief_summary>
	<brief_title>24 Week Study Compare Systemic VEGF-levels Ranibizumab Aflibercept DME .</brief_title>
	<detailed_description>The purpose study compare effect monthly intravitreal injection 0.5 mg ranibizumab 2.0 mg aflibercept systemic VEGF level patient visual impairment due DME 24 week period . In addition , study also assess effect systemic VEGF-A level patient switch aflibercept ranibizumab .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Type 1 Type 2 diabetes mellitus Visual impairment due DME BCVA 78 24 ( 20/3220/320 ) ETDRS letter Stroke myocardial infarction le 3 month prior screen . Presence uncontrolled systolic blood pressure diastolic blood pressure Renal failure require dialysis renal transplant renal insufficiency Untreated diabetes mellitus Use systemic antiVEGF drug within 6 month prior screen . Use systemic inhaled corticosteroid least 30 consecutive day within 3 month prior screen . Women pregnant breast feed menstruate capable become pregnant* practice medically approve method contraception For either eye : Any active periocular ocular infection inflammation Uncontrolled glaucoma Neovascularization iris neovascular glaucoma History treatment antiangiogenic drug For study eye : Atrophy fibrosis involve center fovea time screen baseline . Cataract ( cause significant visual impairment ) , plan cataract surgery study period , vitrectomy , aphakia , glaucoma surgery , severe vitreous hemorrhage , rhegm Irreversible structural damage within 0.5 disc diameter center macula Panretinal laser photocoagulation within 6 month prior randomization . Focal/grid laser photocoagulation within 3 month prior randomization . Any intraocular procedure ( include cataract surgery , YttriumAluminumGarnet capsulotomy ) within 3 month prior baseline anticipate within next 6 month follow Topical ocular corticosteroid administer least 30 consecutive day within 3 month prior screen . Application intravitreal corticosteroid vitreous within 6 month prior screen . Prior application fluocinolonacetonid release implant vitreous within 36 month prior screen . For fellow eye Retinal choroidal neovascularization macula edema cause Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetic Macular Edema .</keyword>
</DOC>